G. Murphy

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

L. Lönn, L. Sjöström, J. Svensson, 1998, The Journal of clinical endocrinology and metabolism.

Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.

L. Quarles, G. Murphy, B. Lobaugh, 1992, The Journal of clinical endocrinology and metabolism.

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

M. Thorner, G. Murphy, D. Krupa, 1997, The Journal of clinical endocrinology and metabolism.

Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males

S. Mohan, C. Ohlsson, J. Svensson, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin‐like growth factor I axis in growth hormone–deficient children

J. Svensson, E. Codner, F. Cassorla, 2001, Clinical pharmacology and therapeutics.

Uremic tumoral calcinosis: preliminary observations suggesting an association with aberrant vitamin D homeostasis.

L. Quarles, G. Murphy, M. Econs, 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Differential production of adrenal steroids by purified cells of the human adrenal cortex is relative rather than absolute.

G. Murphy, L. Young, S. Cunningham, 2003, European journal of endocrinology.